13D Filing: Armistice Capital and Cerecor Inc (CERC)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Armistice Capital 0 3,210,000 0 3,210,000 3,210,000 22.8%
Armistice Capital Master Fund, Ltd 0 3,210,000 0 3,210,000 3,210,000 22.8%
Steven Boyd 0 3,210,000 0 3,210,000 3,210,000 22.8%

Follow Steven Boyd's Armistice Capital

Page 1 of 10 – SEC Filing


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.___)*
Cerecor Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
15671L109
(CUSIP Number)
Evan Thomas
c/o Armistice Capital LLC
510 Madison Avenue
22nd Floor
New York, NY 10022
Telephone Number: 212-231-4930
(Name, Address and Telephone Number of Person Authorized to Receive
Notices and Communications)
April 27, 2017
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d‑1(f) or 240.13d-1(g), check the following box [_].
*          The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 2 of 10 – SEC Filing

CUSIP No.
15671L109
1.
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Armistice Capital, LLC
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
[_]
(b)
[_]
3.
SEC USE ONLY
4.
SOURCE OF FUNDS
AF
5.
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

[_]
6.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
7.
SOLE VOTING POWER
0
8.
SHARED VOTING POWER
3,210,000
9.
SOLE DISPOSITIVE POWER
0
10.
SHARED DISPOSITIVE POWER
3,210,000
11.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,210,000
12.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

[_]
13.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
22.8%
14.
TYPE OF REPORTING PERSON
IA, OO

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 3 of 10 – SEC Filing

CUSIP No.
15671L109
1.
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Armistice Capital Master Fund, Ltd.
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
[_]
(b)
[_]
3.
SEC USE ONLY
4.
SOURCE OF FUNDS
WC
5.
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

[_]
6.
CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
7.
SOLE VOTING POWER
0
8.
SHARED VOTING POWER
3,210,000
9.
SOLE DISPOSITIVE POWER
0
10.
SHARED DISPOSITIVE POWER
3,210,000
11.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,210,000
12.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

[_]
13.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
22.8%
14.
TYPE OF REPORTING PERSON
CO

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 4 of 10 – SEC Filing

CUSIP No.
15671L109
1.
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Steven Boyd
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
[_]
(b)
[_]
3.
SEC USE ONLY
4.
SOURCE OF FUNDS
AF
5.
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

[_]
6.
CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
7.
SOLE VOTING POWER
0
8.
SHARED VOTING POWER
3,210,000
9.
SOLE DISPOSITIVE POWER
0
10.
SHARED DISPOSITIVE POWER
3,210,000
11.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,210,000
12.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

[_]
13.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
22.8%
14.
TYPE OF REPORTING PERSON
IN, HC

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 5 of 10 – SEC Filing

CUSIP No.
15671L109
Item 1.
Security and Issuer.
The name of the issuer is Cerecor Inc., a Delaware corporation (the “Issuer”).  The address of the Issuer’s principal executive offices is 400 E. Pratt Street, Suite 606, Baltimore, Maryland 21202.  This Schedule 13D relates to the Issuer’s Common Stock, $0.001 par value (the “Shares”).
Item 2.
Identity and Background.
(a), (f)
The persons filing this statement are Armistice Capital, LLC, a Delaware limited liability company (“Armistice Capital”), Armistice Capital Master Fund, Ltd., a Cayman Islands corporation (the “Master Fund”), and Steven Boyd, a United States citizen (“Mr. Boyd”, and collectively with Armistice Capital and the Master Fund, the “Reporting Persons”).
(b), (c)
Armistice Capital is an investment adviser registered with the Securities and Exchange Commission (the “SEC”) that is principally engaged in the business of providing investment management services to private investment vehicles, including the Master Fund. The principal business address of Armistice Capital is 510 Madison Avenue, 22nd Floor, New York, New York 10022.
The Master Fund is principally engaged in the business of investing in securities.  The principal business address of the Master Fund is c/o dms Corporate Services Ltd., 20 Genesis Close, P.O. Box 314, Grand Cayman KY1-1104, Cayman Islands.  The board of directors of the Master Fund consists of Steven Boyd, Kevin A. Phillip and Gregory S. Bennett.
Steven Boyd is the managing member of Armistice Capital and a director of the Master Fund.  Mr. Boyd’s business address is 510 Madison Avenue, 22nd Floor, New York, New York 10022.
(d)
None of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)
None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Item 3.
Source and Amount of Funds or Other Consideration.
The funds for the purchase of the 3,210,000 Shares beneficially owned by the Reporting Persons came from working capital of the Master Fund, which is the direct owner of the Shares.  The net investment costs (including commissions, if any) of the Shares beneficially owned by the Reporting Persons is approximately $5,425,956; provided, however, that such amount includes the acquisition of Series A Convertible Preferred Stock and warrants of the Issuer that are not yet beneficially owned by the Reporting Persons since their conversion and exercise into Shares is subject to shareholder approval (as discussed in Item 4 below).  No borrowed funds were used to purchase the Shares, other than any borrowed funds used for working capital purposes (including certain leverage arrangements) in the ordinary course of business.

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 6 of 10 – SEC Filing

Item 4.
Purpose of Transaction.
On April 27, 2017, the Issuer and the Master Fund entered into a securities purchase agreement (the “Securities Purchase Agreement”), pursuant to which the Master Fund agreed to purchase $5 million of the Issuer’s securities, consisting of (i) 2,345,714 Shares at a purchase price of $0.35 per share, (ii) 4,179 shares of the Issuer’s newly-created Series A Convertible Preferred Stock, which are convertible into 11,940,000 Shares, and (iii) warrants to purchase up to 14,285,714 Shares at an exercise price of $0.40 per share.  The Securities Purchase Agreement also provides the Master Fund with certain participation rights in respect of future financings conducted by the Issuer.  Pursuant to NASDAQ Capital Market rules and regulations, the Series A Preferred Stock will only be convertible into Shares, and the warrants will only become exercisable, upon the shareholders of the Issuer voting to approve the private placement.  The Master Fund will not be entitled to vote the Shares issued pursuant to Securities Purchase Agreement.
In addition, pursuant to the terms of the Issuer’s Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Certificate”), (i) as long as the Master Fund maintains beneficial ownership of at least 13% of the Shares, the Master Fund exclusively and as a separate class, will be entitled to elect two directors to the Issuer’s board of directors (the “Board of Directors”), and (ii) as long as the Master Fund maintains beneficial ownership of at least 10% of the Shares, the Master Fund exclusively and as a separate class, will be entitled to elect one director to the Board of Directors.
In connection with the private placement, the Issuer and the Master Fund also entered into a Registration Rights Agreement on April 27, 2017 (the “Registration Rights Agreement”), pursuant to which the Issuer has agreed to file one or more registration statements registering for resale the Shares sold in the private placement and the Shares issuable upon exercise of the warrants and conversion of the Series A Preferred Stock.
On April 28, 2017, the Issuer issued a press release (the “Press Release”) to announce the closing of the $5 million private placement.  Among other things, the Press Release summarizes the material terms of the Securities Purchase Agreement, sets forth how the proceeds of the transaction are anticipated to be used, and announces the rescheduling of the Issuer’s annual meeting of shareholders to June 30, 2017.
The foregoing was a summary of the Press Release and certain material terms of the Securities Purchase Agreement, the Certificate, and the Registration Rights Agreement.  The foregoing descriptions are not, and do not purport to be, complete and are qualified in their entirety by reference to the full text of those documents, which have been filed as Exhibits C, D, E and F, respectively, and are incorporated herein by reference.
The Reporting Persons intend to review their investment in the Issuer on a continuing basis.  Depending on various factors including, without limitation, the Issuer’s financial position, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, participating on the Board of Directors, engaging in discussions with stockholders of the Issuer and others about the Issuer and the Reporting Persons’ investment, proposing changes to the Issuer’s development plans for CERC-501, CERC-301 and CERC-611, reshaping the Issuer’s corporate strategy, recommending business development transactions, proposing changes to management, operations and the structure of the Board of Directors (including the composition of the Board of Directors), purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, or changing their intention with respect to any and all matters referred to in subparagraphs (a) – (j) of Item 4 of Schedule 13D.
Except as otherwise set forth herein, the Reporting Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D.  However, subject to market conditions and in compliance with applicable securities laws, the Reporting Persons reserve the right, at a later date, to affect one or more of such changes.  The Reporting Persons may change the number of Shares they may be deemed to beneficially own in open-market transactions or privately negotiated transactions.  The Reporting Persons may also communicate with the Issuer’s management, Board of Directors and other holders of Shares from time to time.

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 7 of 10 – SEC Filing

Item 5.
Interest in Securities of the Issuer.
(a) – (d)
As of the date hereof, each of the Reporting Persons may be deemed to be the beneficial owner of 3,210,000 Shares, constituting 22.8% of the Shares, based upon 14,081,453 Shares outstanding as of the date hereof.  Each of the Reporting Persons has the sole power to vote or direct the vote of 0 Shares and the shared power to vote or direct the vote of 3,210,000 Shares.  Each of the Reporting Persons has the sole power to dispose or direct the disposition of 0 Shares and the shared power to dispose or direct the disposition of 3,210,000 Shares.  Other than the Shares acquired pursuant to the Securities Purchase Agreement (as summarized in Item 4 above), all Shares beneficially owned by the Reporting Persons were purchased in open market transactions.
The transactions in the Shares by the Reporting Persons during the past sixty days are set forth on Exhibit B.
(e)
N/A
Item 6.
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
The information set forth in Item 4 above is incorporated by reference in its entirety in this Item 6. The Reporting Persons do not have any contract, arrangement, understanding or relationship with any person with respect to securities of the Issuer that is not described in Item 4 above and/or incorporated herein by reference.
Item 7.
Material to be Filed as Exhibits.
Exhibit A:          Joint Filing Agreement
Exhibit B:          Schedule of Transactions in the Shares
Exhibit C:          Press Release of Cerecor Inc., dated April 28, 2017 (incorporated by reference to Exhibit 99.1 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017)
Exhibit D:          Securities Purchase Agreement, dated April 27, 2017 (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017)
Exhibit E:          Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of Cerecor Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017)
Exhibit F:          Registration Rights Agreement, dated April 27, 2017 (incorporated by reference to Exhibit 10.2 to the Form 8-K filed with the SEC by the Issuer on April 28, 2017)

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 8 of 10 – SEC Filing

SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
May 8, 2017
(Date)
Armistice Capital, LLC*
By:  /s/ Steven Boyd
Name: Steven Boyd
Title: Managing Member
Armistice Capital Master Fund, Ltd.
By:  /s/ Steven Boyd
Name: Steven Boyd
Title: Director
Steven Boyd*
/s/ Steven Boyd
* The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interests therein, and this report shall not be deemed an admission that such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose.
Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 9 of 10 – SEC Filing

Exhibit A
AGREEMENT
The undersigned agree that this Schedule 13D, dated May 8 2, 2017, relating to the Common Stock, $0.001 par value, of Cerecor Inc. shall be filed on behalf of the undersigned.
May 8, 2017
(Date)
Armistice Capital, LLC
By:  /s/ Steven Boyd
Name: Steven Boyd
Title: Managing Member
Armistice Capital Master Fund, Ltd.
By:  /s/ Steven Boyd
Name: Steven Boyd
Title: Director
Steven Boyd
/s/ Steven Boyd

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)

Page 10 of 10 – SEC Filing

Exhibit B
Schedule of Transactions in the Shares
Trade Date
Purchase/Sale
Quantity
Price
4/12/2017
Purchase
4,000
$0.55
4/12/2017
Sale
4,000
$0.55
4/27/2017
Purchase
2,345,714
$0.35
4/28/2017
Purchase
450,000
$0.44
5/01/2017
Purchase
105,620
$0.50
5/02/2017
Purchase
146,095
$0.53
5/03/2017
Purchase
68,359
$0.55
5/04/2017
Purchase
28,413
$0.63
5/05/2017
Purchase
15,798
$0.61
5/08/2017
Purchase
50,001
$0.65
SK 27622 0002 7468942

Follow Avalo Therapeutics Inc. (NASDAQ:AVTX)